Title: Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes

Journal Article · · Human Molecular Genetics
DOI: https://doi.org/10.1093/hmg/ddw051 · OSTI ID:1379313
 [1];  [1];  [2];  [2];  [3];  [4];  [5];  [5];  [1]
  1. Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
  2. Univ. of California, Berkeley, CA (United States)
  3. Univ. of Pittsburgh, PA (United States)
  4. Consejo Superior de Investigaciones Cientificas (CSIC), Madrid (Spain)
  5. Univ. of Puerto Rico, San Juan, PR (United States)

Oxidative damage to mitochondria (MT) is a major mechanism for aging and neurodegeneration. We have developed a novel synthetic antioxidant, XJB-5-131, which directly targets MT, the primary site and primary target of oxidative damage. XJB-5-131 prevents the onset of motor decline in an HdhQ(150/150) mouse model for Huntington's disease (HD) if treatment starts early. Here, we report that XJB-5-131 attenuates or reverses disease progression if treatment occurs after disease onset. In animals with well-developed pathology, XJB-5-131 promotes weight gain, prevents neuronal death, reduces oxidative damage in neurons, suppresses the decline of motor performance or improves it, and reduces a graying phenotype in treated HdhQ(150/150) animals relative to matched littermate controls. XJB-5-131 holds promise as a clinical candidate for the treatment of HD.

Research Organization:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
Sponsoring Organization:
National Institutes of Health; USDOE
Grant/Contract Number:
AC02-05CH11231
OSTI ID:
1379313
Journal Information:
Human Molecular Genetics, Journal Name: Human Molecular Genetics Journal Issue: 9 Vol. 25; ISSN 0964-6906
Publisher:
Oxford University PressCopyright Statement
Country of Publication:
United States
Language:
English

References (51)

Current and Future Public Health Challenges journal October 2000
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit journal May 2014
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease journal June 2010
Therapeutic advances in Huntington's Disease: Therapeutic Advances in HD journal July 2015
Analysis of Gene-Specific DNA Damage and Repair Using Quantitative Polymerase Chain Reaction journal October 2000
Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease journal June 2001
Transcription, Epigenetics and Ameliorative Strategies in Huntington’s Disease: a Genome-Wide Perspective journal May 2014
Effects of coenzyme Q10 administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat journal September 2002
Oral Coenzyme Q10 Supplementation in Patients with Nonalcoholic Fatty Liver Disease: Effects on Serum Vaspin, Chemerin, Pentraxin 3, Insulin Resistance and Oxidative Stress journal October 2014
Antioxidants in Huntington's disease journal May 2012
Alzheimer Mechanisms and Therapeutic Strategies journal March 2012
Targeting of XJB-5-131 to Mitochondria Suppresses Oxidative DNA Damage and Motor Decline in a Mouse Model of Huntington’s Disease journal November 2012
Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration journal November 2006
Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice journal May 2004
Mitochondrial DNA damage Is associated with reduced mitochondrial bioenergetics in Huntington's disease journal October 2012
Mitochondrial Diseases of the Brain journal October 2013
Evaluation of cytotoxicity of oils used in coenzyme Q10 Self-Emulsifying Drug Delivery Systems (SEDDS) journal April 2004
Coenzyme Q, oxidative stress and aging journal June 2007
Formation and repair of oxidative damage in the mitochondrial DNA journal July 2014
Huntington's disease knock-in male mice show specific anxiety-like behaviour and altered neuronal maturation journal January 2012
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis journal June 2012
Clinical aspects of coenzyme Q10: An update journal March 2010
Mitochondria-targeted ROS scavenger improves post-ischemic recovery of cardiac function and attenuates mitochondrial abnormalities in aged rats journal December 2014
Targeting Mitochondria journal January 2008
Superoxide Dismutases and Superoxide Reductases journal January 2014
Mitochondrial Targeting of Selective Electron Scavengers:  Synthesis and Biological Analysis of Hemigramicidin−TEMPO Conjugates journal September 2005
Allylic Amines as Key Building Blocks in the Synthesis of ( E )-Alkene Peptide Isosteres journal November 2011
Characterization of Hydantoin Products from One-Electron Oxidation of 8-Oxo-7,8-dihydroguanosine in a Nucleoside Model journal July 2001
Pivotal Role for Two Electron Reduction in 2,3-Dimethoxy-1,4-naphthoquinone and 2-Methyl-1,4-naphthoquinone Metabolism and Kinetics in Vivo That Prevents Liver Redox Stress journal April 2009
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences: Mitochondrial dysfunction in Parkinson's disease journal June 2012
Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity journal February 2011
NIH Image to ImageJ: 25 years of image analysis journal June 2012
Lipidomics identifies cardiolipin oxidation as a mitochondrial target for redox therapy of brain injury journal August 2012
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice: Creatine therapy in Huntington's disease journal April 2003
Neurological abnormalities in a knock-in mouse model of Huntington's disease journal January 2001
Mitochondria‐targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants journal August 2003
Mitochondria‐targeted antioxidants journal August 2015
Neuropathological Classification of Huntingtonʼs Disease journal January 1985
Huntington Disease journal January 1998
Hemigramicidin-TEMPO conjugates: Novel mitochondria-targeted antioxidants journal January 2007
Treatment With a Novel Hemigramicidin-TEMPO Conjugate Prolongs Survival in a Rat Model of Lethal Hemorrhagic Shock journal January 2007
Abnormalities in the Tricarboxylic Acid Cycle in Huntington Disease and in a Huntington Disease Mouse Model journal June 2015
Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism: Coenzyme Q10 and MPTP journal October 2007
Mutant Huntingtin Impairs Axonal Trafficking in Mammalian Neurons In Vivo and In Vitro journal September 2004
Is There a Link between Mitochondrial Reserve Respiratory Capacity and Aging? journal January 2012
Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial journal October 2006
Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington’s Disease journal August 2015
Automated Tracking of Animal Posture and Movement during Exploration and Sensory Orientation Behaviors journal August 2012
Targeting Mitochondrial Dysfunction and Neurodegeneration by Means of Coenzyme Q10 and its Analogues journal September 2011
Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction journal July 2013
Prolonged Intake of Coenzyme Q10 Impairs Cognitive Functions in Mice journal August 2009

Cited By (11)

XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent. text January 2018
Oxidative Stress and Huntington’s Disease: The Good, The Bad, and The Ugly journal October 2016
R-loops: targets for nuclease cleavage and repeat instability journal January 2018
Energy Metabolism and Mitochondrial Superoxide Anion Production in Pre-symptomatic Striatal Neurons Derived from Human-Induced Pluripotent Stem Cells Expressing Mutant Huntingtin journal August 2019
N6-Furfuryladenine is protective in Huntington’s disease models by signaling huntingtin phosphorylation journal July 2018
The interaction of aging and oxidative stress contributes to pathogenesis in mouse and human Huntington disease neurons posted_content December 2019
Hepatic HKDC1 Expression Contributes to Liver Metabolism journal December 2018
XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent journal April 2018
XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent. text January 2018
A Mitochondria-Associated Oxidative Stress Perspective on Huntington’s Disease journal September 2018
Impaired Redox Signaling in Huntington’s Disease: Therapeutic Implications journal March 2019